Abnormal Glucose tolerance-Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Abnormal Glucose Tolerance – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Abnormal Glucose Tolerance pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Abnormal Glucose Tolerance: Overview
Abnormal Glucose tolerance is an umbrella term for a group of metabolic conditions that result in higher than normal blood glucose levels. A condition in which blood sugar is high, but not high enough to be type 2 diabetes. With impaired glucose tolerance one may face a much greater risk of developing diabetes and cardiovascular disease. The WHO (World Health Organisation) indicates that impaired glucose tolerance may be present if people have: Blood glucose of 7.8 mmol/L or more but less than 11.1mmol/L after a 2-hour oral glucose tolerance test OGTT. Various factors increase the risk of developing impaired glucose tolerance including: being overweight or obese, having a family history of diabetes, doing little physical activity, having high blood pressure or high cholesterol and gestational diabetes.
“Abnormal Glucose Tolerance - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Abnormal Glucose Tolerance R&D. The therapies under development are focused on novel approaches to treat/improve Abnormal Glucose Tolerance.
Abnormal Glucose Tolerance Emerging Drugs Chapters
This segment of the Abnormal Glucose Tolerance report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Abnormal Glucose Tolerance Emerging Drugs
HSK7653: Haisco Pharmaceutical Group Co., Ltd.
HSK7653 is a small molecule under investigation in phase II clinical study. The study is being done to evaluate the efficacy, Safety of HSK7653 in Chinese participants with impaired glucose tolerance. HSK7653 is known to inhibit CD26 antigen.
Volagidemab: REMD Biotherapeutics
Volagidemab (formerly REMD 477) is a fully human antibody that specifically binds to and blocks the glucagon receptor functions, being developed by REMD. Currently the drug is in phase I stage of development for Glucose Intolerance.
Further product details are provided in the report……..
Abnormal Glucose Tolerance: Therapeutic Assessment
This segment of the report provides insights about the different Abnormal Glucose Tolerance drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Abnormal Glucose Tolerance
There are approx. 5+ key companies which are developing the therapies for Abnormal Glucose Tolerance. The companies which have their Abnormal Glucose Tolerance drug candidates in the most advanced stage, i.e. phase II include, Haisco Pharmaceutical Group Co., Ltd.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Abnormal Glucose Tolerance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Abnormal Glucose Tolerance: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Abnormal Glucose Tolerance therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Abnormal Glucose Tolerance drugs.
Abnormal Glucose Tolerance Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Abnormal Glucose Tolerance – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Abnormal Glucose Tolerance pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Abnormal Glucose Tolerance: Overview
Abnormal Glucose tolerance is an umbrella term for a group of metabolic conditions that result in higher than normal blood glucose levels. A condition in which blood sugar is high, but not high enough to be type 2 diabetes. With impaired glucose tolerance one may face a much greater risk of developing diabetes and cardiovascular disease. The WHO (World Health Organisation) indicates that impaired glucose tolerance may be present if people have: Blood glucose of 7.8 mmol/L or more but less than 11.1mmol/L after a 2-hour oral glucose tolerance test OGTT. Various factors increase the risk of developing impaired glucose tolerance including: being overweight or obese, having a family history of diabetes, doing little physical activity, having high blood pressure or high cholesterol and gestational diabetes.
“Abnormal Glucose Tolerance - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Abnormal Glucose Tolerance R&D. The therapies under development are focused on novel approaches to treat/improve Abnormal Glucose Tolerance.
Abnormal Glucose Tolerance Emerging Drugs Chapters
This segment of the Abnormal Glucose Tolerance report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Abnormal Glucose Tolerance Emerging Drugs
HSK7653: Haisco Pharmaceutical Group Co., Ltd.
HSK7653 is a small molecule under investigation in phase II clinical study. The study is being done to evaluate the efficacy, Safety of HSK7653 in Chinese participants with impaired glucose tolerance. HSK7653 is known to inhibit CD26 antigen.
Volagidemab: REMD Biotherapeutics
Volagidemab (formerly REMD 477) is a fully human antibody that specifically binds to and blocks the glucagon receptor functions, being developed by REMD. Currently the drug is in phase I stage of development for Glucose Intolerance.
Further product details are provided in the report……..
Abnormal Glucose Tolerance: Therapeutic Assessment
This segment of the report provides insights about the different Abnormal Glucose Tolerance drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Abnormal Glucose Tolerance
There are approx. 5+ key companies which are developing the therapies for Abnormal Glucose Tolerance. The companies which have their Abnormal Glucose Tolerance drug candidates in the most advanced stage, i.e. phase II include, Haisco Pharmaceutical Group Co., Ltd.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Abnormal Glucose Tolerance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Abnormal Glucose Tolerance: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Abnormal Glucose Tolerance therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Abnormal Glucose Tolerance drugs.
Abnormal Glucose Tolerance Report Insights
- Abnormal Glucose Tolerance Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Abnormal Glucose Tolerance drugs?
- How many Abnormal Glucose Tolerance drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Abnormal Glucose Tolerance?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Abnormal Glucose Tolerance therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Abnormal Glucose Tolerance and their status?
- What are the key designations that have been granted to the emerging drugs?
- REMD Biotherapeutics
- Haisco Pharmaceutical Group Co., Ltd.
- Novo Nordisk A/S
- Caelus Pharmaceuticals BV
- HSK7653
- Volagidemab
- Liraglutide Pen Injector
- Intestinimonas-capsules
Introduction
Executive Summary
Abnormal Glucose Tolerance: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Abnormal Glucose Tolerance – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Abnormal Glucose Tolerance companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Abnormal Glucose Tolerance Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HSK7653: Haisco Pharmaceutical Group Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Volagidemab: REMD Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Abnormal Glucose Tolerance Key Companies
Abnormal Glucose Tolerance Key Products
Abnormal Glucose Tolerance- Unmet Needs
Abnormal Glucose Tolerance- Market Drivers and Barriers
Abnormal Glucose Tolerance- Future Perspectives and Conclusion
Abnormal Glucose Tolerance Analyst Views
Abnormal Glucose Tolerance Key Companies
Appendix
Executive Summary
Abnormal Glucose Tolerance: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Abnormal Glucose Tolerance – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Abnormal Glucose Tolerance companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Abnormal Glucose Tolerance Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
HSK7653: Haisco Pharmaceutical Group Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Volagidemab: REMD Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Abnormal Glucose Tolerance Key Companies
Abnormal Glucose Tolerance Key Products
Abnormal Glucose Tolerance- Unmet Needs
Abnormal Glucose Tolerance- Market Drivers and Barriers
Abnormal Glucose Tolerance- Future Perspectives and Conclusion
Abnormal Glucose Tolerance Analyst Views
Abnormal Glucose Tolerance Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Abnormal Glucose Tolerance
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Abnormal Glucose Tolerance
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Table 1 Total Products for Abnormal Glucose Tolerance
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Abnormal Glucose Tolerance
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
